Ocean Biomedical, Inc. specializes in oncology, fibrosis, and infectious disease therapies. They are developing an antibody targeting Chi3l1 and a bi-specific antibody against Chi3l1, PD-1, and CTLA-4 for treating non-small cell lung cancer and glioblastoma multiforme.
Ocean Biomedical, Inc., a biopharmaceutical innovator, specializes in the discovery and development of therapeutic products across key medical domains including oncology, fibrosis, and infectious diseases. The company's robust pipeline includes an antibody therapeutic targeting Chi3l1, alongside a bi-specific antibody combining Chi3l1 inhibition with PD-1 and CTLA-4 targeting, intended for treating non-small cell lung cancer and glioblastoma multiforme. Additionally, Ocean Biomedical is advancing a small molecule therapy targeting Chit1, aimed at addressing Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.
Central to its research efforts, Ocean Biomedical leverages the WPDS platform to develop cutting-edge product candidates. This includes a promising malaria vaccine candidate and a humanized monoclonal antibody therapeutic targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP). The company also explores a small molecule therapy designed to combat malaria by targeting PfGARP, highlighting its commitment to advancing treatments for infectious diseases.
Headquartered in Providence, Rhode Island, Ocean Biomedical operates as a subsidiary of Poseidon Bio, LLC, benefiting from strategic synergies and a supportive infrastructure for accelerating research and development. With a focus on transformative therapies and a dedication to scientific innovation, Ocean Biomedical continues to forge ahead in its mission to improve patient outcomes and address critical medical challenges worldwide.